 The primary pharmacokinetic parameters Cmax, AUC0-tau, and Cmin will be natural log-transformed ln prior to statistical analyses. Any ln-transformed parameter where the observed intra-subject CV for the reference product is at least 30 swr 0.294 will be evaluated using the scaled average bioequivalence SABE method. The GLM procedure of SAS will be used to conduct the SABE analyses, as well as to estimate the intra-subject CV for the reference product. The statistical model for the GLM procedure will contain only a term for SequenceSite. The linearized Scaled Average Bioequivalence statistic and the upper 95 Confidence Bound on the statistic will be estimated. The ratio of geometric means TR will also be calculated. 